Drs Haddad, Bauman, and Mehra discuss the latest data as well as practicalities of using immunotherapy in SCCHN.
This activity is intended for oncologists, surgeons, and pathologists.
The goal of this activity is to discuss the recent advances in the use of immunotherapy for head and neck cancer.
Approximate Time to Complete: 30 minutes
Credit Available: Nov. 29, 2017 - Nov. 29, 2018
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the guideline-recommended care in the management of recurrent/metastatic squamous cell carcinoma of the head and neck
- Have increased knowledge regarding the emerging clinical trial data on the use of immune checkpoint inhibitors alone or in combination in the management of squamous cell carcinoma of the head and neck